Inventor
GRYAZNOV SERGEI
US37 patents
⚠️ This page may combine multiple inventors who share the name “GRYAZNOV SERGEI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GERON CORP
14 patentsUS7321029B2Jan 22, 2008
2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
GERON CORP219 citations99
US7563618B2Jul 21, 2009
Oligonucleotide conjugates
GERON CORP42 citations96
US7494982B2Feb 24, 2009
Modified oligonucleotides for telomerase inhibition
GERON CORP46 citations96
US6835826B2Dec 28, 2004
Oligonucleotide N3′→P5′ Thiophosphoramidates: their synthesis and use
GERON CORP40 citations96
US6608036B1Aug 19, 2003
Oligonucleotide N3′→P5′ thiophosphoramidates: their synthesis and administration to treat neoplasms
GERON CORP57 citations96
US7138383B2Nov 21, 2006
Treating cancer using an oligonucleotide N3′->N5′ thiophosphoramidate
GERON CORP31 citations92
US9657296B2May 23, 2017
Modified oligonucleotides for telomerase inhibition
GERON CORP10 citations84
US9388416B2Jul 12, 2016
Modified oligonucleotides for telomerase inhibition
GERON CORP5 citations84
US9388415B2Jul 12, 2016
Modified oligonucleotides for telomerase inhibition
GERON CORP8 citations84
US8377644B2Feb 19, 2013
2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use
GERON CORP8 citations84
US7989603B2Aug 2, 2011
2′-arabino-fluorooligonucleotide N3′-P5′ phosphoramidates: their synthesis and use
GERON CORP8 citations84
US10196641B2Feb 5, 2019
Modified oligonucleotides for telomerase inhibition
GERON CORP2 citations73
US9822360B2Nov 21, 2017
RNA amidates and thioamidates for RNAi
GERON CORP2 citations73
US10655127B2May 19, 2020
RNA amidates and thioamidates for RNAi
GERON CORP0 citations52
JANSSEN BIOPHARMA INC
7 patentsUS12030907B2Jul 9, 2024
Modified nucleoside phosphoramidites
JANSSEN BIOPHARMA INC2 citations73
US11180524B2Nov 23, 2021
Modified nucleoside phosphoramidites
JANSSEN BIOPHARMA INC4 citations73
US10793859B2Oct 6, 2020
Modified oligonucleotides and methods of use
JANSSEN BIOPHARMA INC2 citations69
US12428441B2Sep 30, 2025
Modified nucleoside phosphoramidites
JANSSEN BIOPHARMA INC0 citations62
US12077757B2Sep 3, 2024
Modified oligonucleotides and methods of use
JANSSEN BIOPHARMA INC1 citations59
US10905767B2Feb 2, 2021
Oligonucleotide constructs and uses thereof
JANSSEN BIOPHARMA INC0 citations56
US12503698B2Dec 23, 2025
GalNAc derivatives
JANSSEN BIOPHARMA INC0 citations51
EXICURE INC
5 patentsUS10208310B2Feb 19, 2019
Anti-TNF compounds
EXICURE INC17 citations90
US10434064B2Oct 8, 2019
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EXICURE INC9 citations82
US10894963B2Jan 19, 2021
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EXICURE INC7 citations81
US10837018B2Nov 17, 2020
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EXICURE INC6 citations81
US10760080B2Sep 1, 2020
Anti-TNF compounds
EXICURE INC5 citations80
UNIV NORTHWESTERN
3 patentsUS10182988B2Jan 22, 2019
Liposomal particles, methods of making same and uses thereof
UNIV NORTHWESTERN17 citations91
US10792251B2Oct 6, 2020
Liposomal particles, methods of making same and uses thereof
UNIV NORTHWESTERN11 citations82
US11883535B2Jan 30, 2024
Liposomal particles, methods of making same and uses thereof
UNIV NORTHWESTERN1 citations70
GRYAZNOV SERGEI
2 patentsEXICURE OPERATING COMPANY
2 patentsUS11123294B2Sep 21, 2021
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EXICURE OPERATING COMPANY5 citations81
US11957788B2Apr 16, 2024
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EXICURE OPERATING COMPANY1 citations70